<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027884</url>
  </required_header>
  <id_info>
    <org_study_id>SNT-III-003</org_study_id>
    <nct_id>NCT01027884</nct_id>
  </id_info>
  <brief_title>Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)</brief_title>
  <acronym>DELOS</acronym>
  <official_title>A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santhera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Phase III study was to assess the efficacy of idebenone on pulmonary
      function, motor function, muscle strength and quality of life in patients with DMD.
      Furthermore, the safety and tolerability of idebenone was assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a Phase III, multicenter, randomized, double-blind, placebo-controlled
      efficacy and safety study. DMD patients (ambulatory and non-ambulatory) at age 10-18 years
      were enrolled at sites in Europe and North America. Study subjects were randomized in a 1:1
      ratio to receive either idebenone (900 mg/day) or placebo 3 times a day with meals for 52
      weeks. The primary endpoint was the difference between Catena®/Raxone® and placebo in the
      change from Baseline to week 52 in Peak Expiratory Flow (PEF as percent predicted, PEF%p, a
      measure of respiratory muscle strength) as measured by hospital-based spirometry. PEF was
      also measured by the patient at home using the hand-held ASMA-1 device (secondary endpoint).
      Other respiratory endpoints included Forced Expiratory Volume in 1 second (as percent
      predicted, FEV1%p, an additional measure of respiratory muscle strength) and Forced Vital
      Capacity (as percent predicted, FVC%p, a measure of restrictive lung disease predictive of
      morbidity and mortality in DMD).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Muscle Strength</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The change from Baseline to Week 52 in muscle strength as measured by Hand-Held Myometry (HHM) was performed following standardized procedures. As almost all patients were non-ambulatory, only analyses of upper limb muscle strength were performed. Results for elbow flexors and for elbow extensors are reported below.The highest value of 3 consecutive measurements with an interval of at least 10 seconds were recorded.
The HHM was measured using MicroFET2, a digital hand held muscle tester. The selected unit of measure was Newtons (N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 52 in Quality of Life Assessed by PedsQL™ Paediatric Quality of Life Inventory</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>PedsQL Quality of Life Inventory contains paediatric HRQOL measurements: Physical, Emotional,Social and School Functioning.
Item Scaling:
5-point Likert scale from 0 (Never) to 4 (Almost always). 3-point scale: 0 (Not at all), 2 (Sometimes) and 4 (A lot) for the Young Child (ages 5-7).
Scores are transformed on a scale from 0 to 100 ( 0=100, 1=75, 2=50, 3=25, 4=0) Total Score: Sum of all the items over the number of items answered on all the Scales.
The values reported below are overall scores on Paediatric Quality of Life Inventory in Child/Teen Report. These scores were obtained by averaging scores for all the described subscales. The overall scores range between 0-100 with 0 = worst outcome and 100= best outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting Adverse Events</measure>
    <time_frame>52 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <condition>Ambulatory Care</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 900 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idebenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idebenone 900 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals</description>
    <arm_group_label>Idebenone</arm_group_label>
    <other_name>CATENA®</other_name>
    <other_name>RAXONE®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 10 - 18 years of age at Baseline.

          2. Signed and dated informed consent.

          3. Documented diagnosis of DMD or severe dystrophinopathy and clinical features
             consistent of typical DMD at diagnosis (i.e. documented delayed motor skills and
             muscle weakness by age 5 years). DMD should be confirmed by mutation analysis in the
             dystrophin gene or by substantially reduced levels of dystrophin protein (i.e. absent
             or &lt;5% of normal) on Western blot or immunostain.

          4. Ability to provide reliable and reproducible repeat PEF within 15% of the first
             assessment (i.e. Baseline vs. Screening).

          5. Patients assessed by the investigator as willing and able to comply with the
             requirements of the study, possess the required cognitive abilities and are able to
             swallow study medication.

        Exclusion Criteria:

          1. Patients dependent on assisted ventilation at Screening and/or Baseline (defined as
             non-invasive nocturnal ventilation, daytime non-invasive ventilation or continuous
             invasive ventilation).

          2. Patients with documented DMD-related hypoventilation for which assisted ventilation is
             needed according to current standard of care guidelines (e.g. FVC&lt; 30%) or is required
             in the opinion of the Investigator.

          3. Patients with a percent predicted PEF &gt; 80% at Baseline.

          4. Patients unable to form a mouth seal to allow precise respiratory flow measurements
             and mouth pressures.

          5. Symptomatic heart failure (high probability of death within one year of Baseline)
             and/or symptomatic ventricular arrhythmias.

          6. Participation in the previous Phase II or Phase II Extension study (SNT-II-001 or
             SNT-II-001-E) for idebenone.

          7. Participation in any other therapeutic trial and/or intake of any investigational drug
             within 90 days prior to Baseline.

          8. Use of carnitine, creatine, glutamine, oxatomide, or any herbal medicines within 30
             days prior to Baseline.

          9. Use of coenzyme Q10 or vitamin E (if taken at a dose of 5 times above the daily
             physiological requirement) within 30 days prior to Baseline.

         10. Any previous use of idebenone.

         11. Any concomitant medication with a depressive or stimulating effect on respiration or
             the respiratory tract.

         12. Planned or expected spinal fixation surgery during the study period (as judged by the
             investigator).

         13. Asthma, bronchitis/COPD, bronchiectasis, emphysema, pneumonia or the presence of any
             other non-DMD respiratory illness that affects PEF.

         14. Chronic use of beta-2 agonists or any use of other bronchodilating medication (e.g.
             inhaled steroids, sympathomimetics, anticholinergics).

             Please note: Chronic use if defined as a daily intake for more than 14 days.

         15. Moderate or severe hepatic impairment or severe renal impairment.

         16. Prior or ongoing medical condition or laboratory abnormality that in the
             Investigator's opinion could adversely affect the safety of the subject.

             Please note: Patients who suffer from a severe, unstable condition including (but not
             limited to) cancer, auto-immune diseases, haematological diseases, metabolic disorders
             or immunodeficiencies, and who are at risk of an aggravation unrelated to the study
             condition, can only be included in the study if accepted in writing by the Sponsor's
             Medical Monitor.

         17. Relevant history of or current drug or alcohol abuse or use of any tobacco/marijuana
             products/smoking

         18. Known individual hypersensitivity to idebenone or to any of the ingredients/excipients
             of the study medication

         19. Systemic glucocorticoid therapy

               1. Chronic use of systemic glucocorticoid therapy for DMD related conditions within
                  12 months of Baseline (the &quot;12 month non-use period&quot;)

               2. More than 2 rounds of acute systemic glucocorticoid burst therapy (of ≤2 week
                  duration) for non-DMD related conditions within the 12 month non-use period

               3. Use of any round of systemic glucocorticoid burst therapy of longer than 2 weeks
                  duration within the 12 month non-use period

               4. Use of systemic glucocorticoid burst therapy less than 8 weeks prior to baseline
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Gunnar Buyse, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven, B-3000, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Ulrike Schara, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Essen, D-45122 Essen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ass. Prof. Jan Verschuuren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center (LUMC), 2300 RC Leiden, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Pierre-Yves Jeannet, Médecin Associé, MER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unité de Neuropédiatrie, CHUV - BH11, 1011 Lausanne-CH, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Thomas Voit, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Pierre et Marie curie VI - Institut de Myologie - groupe hospitalier Pitié Salpétrière - 47/83 boulevard de l'hôpital, 75651 Paris Cedex 13, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Thomas Sejersen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Astrid Lindgrens Barnsjukhus- Karolinska Universitetssjukhuset, SE-17176 Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Günther Bernert, Prim. Univ. Doz.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vorstand der Abteilung für Kinder- und Jugendheilkunde, Gottfried v. Preyer'sches Kinderspital, 1100 Wien, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gihan Tennekoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Neurology - The Children's Hospital of Philadelphia - 34th Street and Civic Center Blvd, Philadelphia, PA 19104-1771, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marie Cuisset, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Roger Salengro, CHRU, Service de neurologie infantile, Lille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Iannaccone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center, TX, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Sparks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Charlotte-Mecklenburg Hospital Authority, Charlotte, NC, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janbernd Kirschner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik Freiburg Zentrum für Kinderheilkunde und Jugendmedizin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Grazia Nadia D'Angelo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS &quot;Eugenio Medea&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ksenija Gorni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Niguarda Ca'Granda Centro Clinico Nemo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan W. Burnette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry Byrne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Apkon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ericka Simpson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Neurological Institute, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig McDonald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luisa Politano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria della Seconda Università degli Studi di Napoli</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Camacho Salas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Jesus Vilchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari y Politècnic La Fe de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center, Neurosciences and Spine Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-1771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Carell, Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Günther Bernert, Prim. Univ. Doz.</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven- Children Hospital</name>
      <address>
        <city>Leuven</city>
        <zip>B - 3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Thomas Voit , MD, PhD</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Zentrum für Kinderheikunde</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Freiburg Zentrum für Kinderheilkunde und Jugendmedizin</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS &quot;Eugenio Medea&quot;</name>
      <address>
        <city>Bosisio Parini, Lecco</city>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Niguarda Ca' Granda Centro Clinico Nemo</name>
      <address>
        <city>Milan</city>
        <zip>20162,</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria della Seconda Università degli Studi di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ass. Prof. Jan Verschuuren , MD, PhD</name>
      <address>
        <city>Leiden</city>
        <state>P.O. Box 9600</state>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Thomas Sejersen, MD, PhD</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV Lausanne Neuropediatrie</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.santhera.com</url>
  </link>
  <results_reference>
    <citation>Buyse GM, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T; DELOS Study Group. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015 May 2;385(9979):1748-1757. doi: 10.1016/S0140-6736(15)60025-3. Epub 2015 Apr 20.</citation>
    <PMID>25907158</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>June 15, 2015</results_first_submitted>
  <results_first_submitted_qc>September 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2015</results_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idebenone</keyword>
  <keyword>Duchenne Muscular Dystrophy (DMD)</keyword>
  <keyword>Respiratory function</keyword>
  <keyword>Ambulatory and non-ambulatory patients</keyword>
  <keyword>Subjects not using glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruiting centres were in Belgium, Germany, the Netherlands, Switzerland, France, Sweden, Austria, Italy, Spain, and the USA. Patients were enrolled between July 27, 2009 (study start date), and Dec 14, 2012; the study end date (last patient completed the study) was Jan 14, 2014.</recruitment_details>
      <pre_assignment_details>65 patients were randomly assigned and two patients were allocated to the same treatment as their randomly assigned siblings. One patient never took study medication, resulting in 66 patients who were treated and included in the safety population (34 in the placebo group and 32 in the idebenone group).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Two matching placebo tablets were taken three times a day with meals</description>
        </group>
        <group group_id="P2">
          <title>Idebenone</title>
          <description>Two150 mg tablets were taken three times a day with meals (total dose 900 mg daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Spinal fixation surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Two matching placebo tablets were taken three times a day with meals</description>
        </group>
        <group group_id="B2">
          <title>Idebenone</title>
          <description>Two150 mg tablets were taken three times a day with meals (total dose 900 mg daily).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="2.5"/>
                    <measurement group_id="B2" value="13.5" spread="2.7"/>
                    <measurement group_id="B3" value="14.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52</title>
        <description>Change from Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>This analysis was performed on the ITT population(n=64). This population included all randomized patients who received at least one dose of the study medication and provided at least one post-Baseline assessment. It excluded siblings who had been allocated to the same study treatment as a randomized sibling.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two matching placebo tablets were taken three times a day with meals</description>
          </group>
          <group group_id="O2">
            <title>Idebenone</title>
            <description>Two150 mg tablets were taken three times a day with meals (total dose 900 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52</title>
          <description>Change from Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52</description>
          <population>This analysis was performed on the ITT population(n=64). This population included all randomized patients who received at least one dose of the study medication and provided at least one post-Baseline assessment. It excluded siblings who had been allocated to the same study treatment as a randomized sibling.</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.84" lower_limit="-12.73" upper_limit="-4.95"/>
                    <measurement group_id="O2" value="-2.57" lower_limit="-6.68" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52</title>
        <description>Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>This analysis was performed on the ITT population(n=64). This population included all randomized patients who received at least one dose of the study medication and provided at least one post-Baseline assessment. It excluded siblings who had been allocated to the same study treatment as a randomized sibling.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 900 mg/day
Placebo: Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals</description>
          </group>
          <group group_id="O2">
            <title>Idebenone</title>
            <description>Idebenone 900 mg/day
Idebenone: Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52</title>
          <description>Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52</description>
          <population>This analysis was performed on the ITT population(n=64). This population included all randomized patients who received at least one dose of the study medication and provided at least one post-Baseline assessment. It excluded siblings who had been allocated to the same study treatment as a randomized sibling.</population>
          <units>percentage of Predicted FVC</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.95" lower_limit="-11.47" upper_limit="-6.42"/>
                    <measurement group_id="O2" value="-5.67" lower_limit="-8.36" upper_limit="-2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Muscle Strength</title>
        <description>The change from Baseline to Week 52 in muscle strength as measured by Hand-Held Myometry (HHM) was performed following standardized procedures. As almost all patients were non-ambulatory, only analyses of upper limb muscle strength were performed. Results for elbow flexors and for elbow extensors are reported below.The highest value of 3 consecutive measurements with an interval of at least 10 seconds were recorded.
The HHM was measured using MicroFET2, a digital hand held muscle tester. The selected unit of measure was Newtons (N).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The number of patients (N) in each treatment group is the number of patients with baseline assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two matching placebo tablets were taken three times a day with meals</description>
          </group>
          <group group_id="O2">
            <title>Idebenone</title>
            <description>Two150 mg tablets were taken three times a day with meals (total dose 900 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Muscle Strength</title>
          <description>The change from Baseline to Week 52 in muscle strength as measured by Hand-Held Myometry (HHM) was performed following standardized procedures. As almost all patients were non-ambulatory, only analyses of upper limb muscle strength were performed. Results for elbow flexors and for elbow extensors are reported below.The highest value of 3 consecutive measurements with an interval of at least 10 seconds were recorded.
The HHM was measured using MicroFET2, a digital hand held muscle tester. The selected unit of measure was Newtons (N).</description>
          <population>The number of patients (N) in each treatment group is the number of patients with baseline assessments</population>
          <units>Newtons</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Elbow Flexors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="-4.16" upper_limit="4.41"/>
                    <measurement group_id="O2" value="-2.32" lower_limit="-6.73" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elbow Extensors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="-2.53" upper_limit="5.18"/>
                    <measurement group_id="O2" value="0.26" lower_limit="-3.95" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 52 in Quality of Life Assessed by PedsQL™ Paediatric Quality of Life Inventory</title>
        <description>PedsQL Quality of Life Inventory contains paediatric HRQOL measurements: Physical, Emotional,Social and School Functioning.
Item Scaling:
5-point Likert scale from 0 (Never) to 4 (Almost always). 3-point scale: 0 (Not at all), 2 (Sometimes) and 4 (A lot) for the Young Child (ages 5-7).
Scores are transformed on a scale from 0 to 100 ( 0=100, 1=75, 2=50, 3=25, 4=0) Total Score: Sum of all the items over the number of items answered on all the Scales.
The values reported below are overall scores on Paediatric Quality of Life Inventory in Child/Teen Report. These scores were obtained by averaging scores for all the described subscales. The overall scores range between 0-100 with 0 = worst outcome and 100= best outcome</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The number of patients (N) in each treatment group is the number of patients with Baseline assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two matching placebo tablets were taken three times a day with meals</description>
          </group>
          <group group_id="O2">
            <title>Idebenone</title>
            <description>Two150 mg tablets were taken three times a day with meals (total dose 900 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 52 in Quality of Life Assessed by PedsQL™ Paediatric Quality of Life Inventory</title>
          <description>PedsQL Quality of Life Inventory contains paediatric HRQOL measurements: Physical, Emotional,Social and School Functioning.
Item Scaling:
5-point Likert scale from 0 (Never) to 4 (Almost always). 3-point scale: 0 (Not at all), 2 (Sometimes) and 4 (A lot) for the Young Child (ages 5-7).
Scores are transformed on a scale from 0 to 100 ( 0=100, 1=75, 2=50, 3=25, 4=0) Total Score: Sum of all the items over the number of items answered on all the Scales.
The values reported below are overall scores on Paediatric Quality of Life Inventory in Child/Teen Report. These scores were obtained by averaging scores for all the described subscales. The overall scores range between 0-100 with 0 = worst outcome and 100= best outcome</description>
          <population>The number of patients (N) in each treatment group is the number of patients with Baseline assessments.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" lower_limit="-1.77" upper_limit="6.69"/>
                    <measurement group_id="O2" value="-1.34" lower_limit="-5.99" upper_limit="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Reporting Adverse Events</title>
        <time_frame>52 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Two matching placebo tablets were taken three times a day with meals</description>
          </group>
          <group group_id="O2">
            <title>Idebenone</title>
            <description>Two150 mg tablets were taken three times a day with meals (total dose 900 mg daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Reporting Adverse Events</title>
          <units>percentage of patients reporting AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Two matching placebo tablets were taken three times a day with meals</description>
        </group>
        <group group_id="E2">
          <title>Idebenone</title>
          <description>Two150 mg tablets were taken three times a day with meals (total dose 900 mg daily).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomitig</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendinous contracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pulmunary microemboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood phosporus increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Gunnar Buyse</name_or_title>
      <organization>University Hospital Leuven-Children Hospital</organization>
      <phone>+32 016343845</phone>
      <email>gunnar.buyse@uzleuven.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

